PRESS RELEASE

Doctors from Columbia University visit PBHRF—

(Prasanta Banerji Homoeopathic Research Foundation)—

to study the Banerji Protocol of homeopathy treatment for paediatric cancer

Kolkata, November 3, 2007: The alarming increase in the number of children afflicted with cancer in recent years has become a subject of serious concern internationally.

The well-known Columbia University in the USA has initiated an Intergrative Therapies Program for Children with Cancer in its Division of Pediatric Oncology. Dr Elena Ladas and Dr Kara Kelly along with their three colleagues from Columbia University spent the entire day at PBHRF, Kolkata meeting over thirty cancer patients (pediatric), observing individual cases and interacting with Dr Prasanta Banerji, Founder and Managing Trustee, Dr Pratip Banerji, Co-Founder and Dy. Managing Trustee and other senior senior doctors of PBHRF to get a first-hand perspective on the Banerji Protocol of homoeopathic treatment for cancer

Classical homoeopathy has no specific remedy for any disease by name, but it has specificity for each individual case of disease. This approach of treating patients, on the basis of symptoms only, is basically a must in long standing chronic diseases, and changes from patient to patient.

The Banerji Protocol is a new method of treatment. Specific medicines are prescribed for specific diseases. Diseases are diagnosed with the use of modern/state-of-the-art methods. This is done because modern diagnostic approaches incorporate and help in the selection of medicines so that specific medicines could be easily prescribed for specific diseases. This is not practised in classical homoeopathy.

The concept of prescribing a specific homoeopathic medicine for a disease on the basis of symptoms was first perceived and practised by Late Dr. Pareshnath Banerji. With the passage of time and the availability of new diagnostic tools like Ultrasonography, MRIs, cancer markers and other advanced tests, Drs Prasanta and Pratip Banerji were able to further streamline the treatment protocols accurately. The efficiency of this streamlining is reflected by the encouraging results of the Banerji Protocol.

Dr Elena Ladas, MS, RD is the Director of the Integrative Therapies Program, Columbia University, U.S.A. Dr Ladas serves as Complementary/Alternative Medicine Chair for the American Dietetics Association’s Oncology Nutrition Diatetic Practice Group. She is also a member of the Children’s Oncology Group Nutrition Task Force Steering Committee, the National Cancer Institute’s PDQ Complementary and Alternative Medicine Editorial Board and Advisory Board, and of the Children’s Oncology Group’s steering committee for complementary/alternative medicine.

Dr Kara Kelly, MD, is the Medical Director of the Integrative Therapies Program for Children with Cancer. She is a pediatric oncologist with clinical expertise in the treatment of children with leukemia, lymphoma and histiolytic disorders. She currently serves as chair of the committee for complementary/alternative medicine at the Children’s Oncology Group, the largest research consortium of pediatric oncology centres in the United States and Canada. Dr Kelly is a member of the National Cancer Institute’s PDQ Complementary and Alternative Medicine Editorial Board.